Gene variants may raise lung cancer risk in Never-Smokers
NCT ID NCT07273279
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will analyze genetic data from 100,000 people to see if variations in aldehyde-metabolizing genes (ADH1B and ALDH family) are linked to lung cancer risk, especially in people who have never smoked. The goal is to understand how these genes might influence the development of lung cancer and its subtypes. No treatment is being tested; this is purely an observational genetic study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify people with higher genetic risk for lung cancer, potentially leading to better screening or prevention strategies.
- What could go wrong
- This is an observational study that only looks at genetic associations, not a treatment trial. It may not find clear links, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONDITION/DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which lung biopsy method is safer and more accurate?
- Light-Based blood test may spot lung cancer early
- Could a nebulized cocktail make lung scopes less Cough-Inducing?
- Can AI be a Pathologist's second opinion?
- A personalized approach to breathlessness: could a stepped-care program offer relief for lung cancer patients?
- Common mucus-thinning drugs may improve outcomes in COPD patients with lung cancer